Table 4. HER2 mutation status of five HER2-positive MBC patients.
| Sample.ID | ERBB2 | ER | PR | DFS* after surgery followed by adjuvant trastzumab (months) | 1st-line treatment | PFS† to 1st-line treatment | 2nd-line treatment | PFS to 2nd-line treatment | HER2 mutation in archival breast tissue |
|---|---|---|---|---|---|---|---|---|---|
| OS226 | p.P420fs (0.22) | Negative | Negative | 14 | Lapatinib + Capecitabine | 4 | Gemcitabine + Vinorelbine | 9 | Not available |
| OS240 | S413L (0.01) | Negative | Negative | Initial stage IV | Trastuzumab + Paclitaxel | 38 | Lapatinib + capecitabine | 6 | S413L (0.01) |
| OS256 | S72A (0.01) | Negative | Negative | 9 | T-DM1 | 12 | Trastuzumab + Docetaxel | 1 | Not available |
| OS251 | P562S (0) | Negative | Negative | 18 | Trastuzumab + Paclitaxel | 12 | Lapatinib + Capecitabine | 2 | P562S (0) |
| OS321 | Q692X (0.02) | Negative | Negative | 15 | Trastuzumab + Docetaxel | 8 | Lapatinib + Capecitabine | 1.5 | Q692X (0.03) |
*
DFS: disease free survival
†
PFS: progression free survival